Mineralys Therapeutics reported total assets of $667.85M and total liabilities of $116.94M for the quarter ended Jun 2026, up 98.9% year over year. This balance sheet covers 18 quarters of results from Mar 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||
| Current Assets | ||||||||||||||||||
| Cash & EquivalentsCash & Equiv. | 87.70M | 138.25M | 101.14M | 86.30M | 49.30M | 90.42M | 67.86M | 97.27M | 114.09M | 165.01M | 101.79M | 217.60M | 172.92M | 112.78M | 138.27M | |||
| Prepaid Assets | 2.70M | 4.63M | 8.39M | 11.61M | 12.54M | 8.25M | 6.89M | 4.13M | 7.16M | 11.48M | 10.35M | 6.17M | 4.75M | 6.41M | 4.39M | |||
| Current Assets | 112.81M | 275.27M | 269.49M | 265.38M | 249.10M | 346.82M | 318.00M | 267.73M | 205.35M | 354.51M | 335.27M | 599.80M | 661.39M | 652.47M | 665.80M | |||
| Non-Current Assets | ||||||||||||||||||
| Property, Plant & Equipment (Net) | 0.05M | 0.04M | 0.07M | 0.05M | 0.04M | 0.02M | 0.01M | 0.04M | 0.03M | 0.03M | ||||||||
| Long-Term Investments | 31.12M | 21.68M | 12.13M | 2.48M | ||||||||||||||
| Other Non-Current Assets | 1.63M | 0.04M | 0.05M | 0.05M | 0.05M | 0.38M | 0.45M | 0.45M | 0.50M | 0.40M | 0.43M | 0.14M | 0.38M | 0.36M | 2.02M | |||
| Non-Current Assets | 1.63M | 31.16M | 21.73M | 12.18M | 2.53M | 0.43M | 0.49M | 0.52M | 0.55M | 0.43M | 0.46M | 0.15M | 0.42M | 0.39M | 2.05M | |||
| Assets | 114.44M | 306.44M | 291.22M | 277.56M | 251.64M | 347.25M | 318.49M | 268.25M | 205.90M | 354.94M | 335.72M | 599.95M | 661.81M | 652.86M | 667.85M | |||
| Liabilities | ||||||||||||||||||
| Current Liabilities | ||||||||||||||||||
| Accounts Payables | 1.91M | 2.39M | 2.20M | 5.57M | 0.60M | 4.26M | 1.71M | 3.11M | 0.48M | 0.37M | 3.16M | 1.12M | 2.02M | 1.12M | 1.07M | |||
| Payables | 1.91M | 2.39M | 2.20M | 5.57M | 0.60M | 4.26M | 1.71M | 3.11M | 0.48M | 0.37M | 3.16M | 1.12M | 2.02M | 1.12M | 1.07M | |||
| Accumulated Expenses | 6.16M | 8.17M | 4.01M | 7.97M | 9.88M | 14.94M | 26.69M | 28.21M | 14.17M | 13.01M | 19.01M | 22.40M | 13.10M | 13.60M | 18.25M | |||
| Total Current Liabilities | 8.07M | 10.56M | 6.21M | 13.54M | 10.48M | 19.20M | 28.40M | 31.32M | 14.65M | 13.39M | 22.17M | 23.52M | 15.11M | 14.72M | 19.32M | |||
| Non-Current Liabilities | ||||||||||||||||||
| Non-Current Debt | 97.62M | |||||||||||||||||
| Preferred Stock Liabilities | 40.99M | 117.66M | 117.66M | 117.66M | ||||||||||||||
| Total Liabilities | 30.48M | 36.93M | 43.41M | 166.71M | 10.56M | 6.21M | 13.54M | 10.48M | 19.20M | 28.40M | 31.32M | 14.65M | 13.39M | 22.17M | 23.52M | 15.11M | 14.72M | 116.94M |
| Shareholder's Equity | ||||||||||||||||||
| Total Debt | 97.62M | |||||||||||||||||
| Common Equity | -30.48M | -36.93M | -43.41M | -52.27M | 295.88M | 285.01M | 264.01M | 241.15M | 328.05M | 290.10M | 236.93M | 191.26M | 341.56M | 313.55M | 576.43M | 646.69M | 638.14M | 550.92M |
| Liabilities and Shareholders Equity | 114.44M | 306.44M | 291.22M | 277.56M | 251.64M | 347.25M | 318.49M | 268.25M | 205.90M | 354.94M | 335.72M | 599.95M | 661.81M | 652.86M | 667.85M | |||
| Retained Earnings | -52.81M | 361.29M | 362.56M | 364.33M | 365.86M | 484.26M | 487.32M | 490.50M | 493.77M | 686.28M | 701.55M | 1,001.35M | 1,103.85M | 1,134.64M | 1,288.49M | |||
| Treasury Shares | 86.33M | 136.51M | 136.51M | 136.51M |